News >

Novel Therapies Lower Symptom Burden, Improve Survival in NETs

Caroline Seymour
Published: Wednesday, Apr 03, 2019

Kunal C. Kadakia, MD

Kunal C. Kadakia, MD

In recent years, positive data from 7 randomized phase III clinical trials have been reported in the field of neuroendocrine tumors (NETs), among which the PROMID, CLARINET, and NETTER-1 trials have demonstrated the greatest impact on the space.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication